trending Market Intelligence /marketintelligence/en/news-insights/trending/nw8jrntapveptqopm2q-kw2 content esgSubNav
In This List

Editas Medicine appoints former Patheon CEO as chairman

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Editas Medicine appoints former Patheon CEO as chairman

Editas Medicine, Inc. appointed James Mullen as board chairman, effective March 28.

Mullen previously served as CEO of Patheon NV until the company's acquisition by Thermo Fisher Scientific Inc.

In addition, the Cambridge, Mass.-based biotechnology company said its co-founder Alexis Borisy and John Mendlein stepped down from the company's board.

Borisy joined the board in 2013. Mendlein, who is Moderna Therapeutics Inc.'s president of corporate and product strategy, joined Editas' board in 2016.